(ORDO NEWS) — Irritable bowel syndrome (IBS) is a prototype functional bowel disorder affecting about 11% of the global population. IBS is a chronic disorder, characterized by a variety of disabling symptoms and associated manifestations, which significantly diminish quality of life in patients.
Given the still limited clinically relevant data about its pathophysiology, IBS has a strong therapeutic unmet need affecting clinical practice of physicians in most countries
IBS symptoms can be triggered by multiple mechanisms, including altered gut-brain axis cross-talk, stress, enteric nerve-immune system interactions, previous gastrointestinal infections, sensory-motor abnormalities, and a variety of luminal factors such as dietary factors, altered epithelial barrier and gut microbiota changes (i.e. ‘dysbiosis’).
Deciphering the complexity is a fundamental step to better manage and treat patients with IBS. In this collection, BMC Medicine will include articles providing a clinically relevant view of the most recent findings on this multifaceted condition.
We are particularly interested in the following topics:
- Food and IBS
- New therapies and advances
- In search of biomarkers: new diagnostic tests
- The microbiota in IBS
- Pathophysiological mechanisms
- The clinical conundrum: Overlapping functional syndromes
- IBS and most commonly associated extraintestinal manifestations
We are principally interested in contributions that can be readily understood by a broad audience, with implications not only for researchers, but also clinical practitioners, policy makers, and public health.
Contact us: [email protected]